Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Stefan S. De Buck
Observed names:
S. S. De Buck,
Stefan S De Buck
Institution:
Novartis (Switzerland)
Observed institutions:
Novartis (Switzerland),
Johnson & Johnson (United States),
Janssen (Belgium),
Erasmus MC,
Vall d'Hebron Hospital Universitari,
Laboratoire National de Santé,
Novartis Institutes for BioMedical Research,
Centre de Recherche Public de la Santé
show all 8
OpenAlex ID:
A5110003288
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
2011
·
Johanna C. Bendell
, Jordi Rodon
, et al.
·
Journal of Clinical Oncology
·
731
PDF
Prediction of Human Pharmacokinetics Using Physiologically Based Modeling: A Retrospective Analysis of 26 Clinically Tested Drugs
2007
·
Stefan S. De Buck
, Vikash K. Sinha
, et al.
·
Drug Metabolism and Disposition
·
271
The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools
2007
·
Stefan S. De Buck
, Vikash K. Sinha
, et al.
·
Drug Metabolism and Disposition
·
104
Physiologically based approaches towards the prediction of pharmacokinetics:in vitro–in vivoextrapolation
2007
·
Stefan S De Buck
, Claire E Mackie
·
Expert Opinion on Drug Metabolism & Toxicology
·
65
A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.
2010
·
J. Baselga
, M. J. De Jonge
, et al.
·
Journal of Clinical Oncology
·
55
Predicting Oral Clearance in Humans: How Close Can We Get with Allometry?
2008
·
Vikash K Sinha
, Stefan S De Buck
, et al.
·
Clinical Pharmacokinetics
·
52
Population pharmacokinetics and pharmacodynamics of BYL 719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies
2014
·
Stefan S. De Buck
, Annamaria Jakab
, et al.
·
British Journal of Clinical Pharmacology
·
43
Specific Antibody Modulates Absorptive Transport and Metabolic Activation of Benzo[a]pyrene across Caco-2 Monolayers
2005
·
Stefan S. De Buck
, Patrick Augustijns
, et al.
·
Journal of Pharmacology and Experimental Therapeutics
·
29
A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors.
2012
·
Philippe Bedard
, Josep Tabernero
, et al.
·
Journal of Clinical Oncology
·
24
Towards a Better Prediction of Peak Concentration, Volume of Distribution and Half-Life after Oral Drug Administration in Man, Using Allometry
2011
·
Vikash K. Sinha
, Karin Vaarties
, et al.
·
Clinical Pharmacokinetics
·
23
Modulation of the metabolism and adverse effects of benzo[a]pyrene by a specific antibody: a novel host factor in environmental carcinogenesis?
2005
·
S. S. De Buck
, Fabienne B Bouche
, et al.
·
Carcinogenesis
·
21
Effects of antibodies induced by a conjugate vaccine on 4‐(methylnitrosamino)‐1‐(3‐pyridyl)‐1‐butanone absorptive transport, metabolism, and proliferation of human lung cells
2009
·
Stefan S. De Buck
, Mario T. Schellenberger
, et al.
·
International Journal of Cancer
·
12
Cardio-vascular safety beyond hERG: in silico modelling of a guinea pig right atrium assay
2009
·
Luca A. Fenu
, Ard Teisman
, et al.
·
Journal of Computer-Aided Molecular Design
·
6
Show more works
View as search
Works count:
13
Citation count:
1,437
H-index:
12
I10-index:
12
Year
Topic
Type